Investors

Investors

Corporate Profile

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in second-line acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its recently opened GMP manufacturing site in Princeton, New Jersey, USA.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –November 30, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Dec. 11, 2017-- Regulatory News : Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol : ERYP) &
View HTML
Toggle Summary Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –November 30, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Dec. 11, 2017-- Regulatory News : Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol : ERYP) &
View HTML
Toggle Summary ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML
ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML Conference call and webcast to take place Monday, December 11th at 10:00 a.m. EST LYON, France - December 8, 2017 - ERYTECH Pharma (Euronext Paris: ERYP) (Nasdaq: ERYP) ("ERYTECH"), a clinical-stage
View HTML
Toggle Summary ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML
Conference call and webcast to take place Monday, December 11th at 10:00 a.m. EST LYON, France --(BUSINESS WIRE)--Dec. 8, 2017-- Regulatory News : ERYTECH Pharma (Euronext Paris: ERYP) (Nasdaq: ERYP) ("ERYTECH"), a clinical-stage biopharmaceutical company developing innovative therapies by
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Jun 26, 2020 at 2:00 PM CEST

Annual General Meeting

Summary Toggle Sep 21, 2020

Business Update and Financial Highlights for the 2nd Quarter of 2020 (after U.S. market close)

Summary Toggle Sep 22, 2020 at 8:30 AM EDT

Erytech Pharma 2nd Quarter of 2020 Conference Call and Webcast

RECEIVE E-MAIL ALERTS

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Top